ICU Medical, Inc. $ICUI Shares Sold by Prudential Financial Inc.

Prudential Financial Inc. lowered its stake in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 2.8% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 59,831 shares of the medical instruments supplier’s stock after selling 1,706 shares during the period. Prudential Financial Inc.’s holdings in ICU Medical were worth $7,907,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in ICUI. Cullen Frost Bankers Inc. acquired a new stake in ICU Medical during the 2nd quarter worth approximately $38,000. Blue Trust Inc. raised its stake in shares of ICU Medical by 17.6% during the second quarter. Blue Trust Inc. now owns 942 shares of the medical instruments supplier’s stock worth $124,000 after purchasing an additional 141 shares during the last quarter. AlphaQuest LLC lifted its holdings in shares of ICU Medical by 3,058.3% during the second quarter. AlphaQuest LLC now owns 1,516 shares of the medical instruments supplier’s stock worth $200,000 after purchasing an additional 1,468 shares during the period. United Services Automobile Association acquired a new stake in shares of ICU Medical during the first quarter worth $218,000. Finally, Johnson Investment Counsel Inc. grew its position in ICU Medical by 17.7% in the 2nd quarter. Johnson Investment Counsel Inc. now owns 1,699 shares of the medical instruments supplier’s stock valued at $225,000 after buying an additional 256 shares during the last quarter. Institutional investors and hedge funds own 96.10% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have commented on ICUI. Wall Street Zen downgraded shares of ICU Medical from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th. Piper Sandler boosted their price target on shares of ICU Medical from $153.00 to $172.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. KeyCorp lifted their price objective on ICU Medical from $173.00 to $175.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of ICU Medical in a research note on Wednesday, October 8th. Finally, Raymond James Financial reduced their price target on ICU Medical from $187.00 to $180.00 and set a “strong-buy” rating for the company in a report on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, ICU Medical presently has a consensus rating of “Moderate Buy” and a consensus target price of $181.75.

Insider Buying and Selling at ICU Medical

In related news, VP Virginia Ruth Sanzone sold 930 shares of the business’s stock in a transaction dated Tuesday, November 11th. The shares were sold at an average price of $142.34, for a total value of $132,376.20. Following the sale, the vice president directly owned 5,456 shares in the company, valued at $776,607.04. The trade was a 14.56% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Elisha W. Finney sold 1,285 shares of the stock in a transaction dated Tuesday, November 11th. The shares were sold at an average price of $140.42, for a total transaction of $180,439.70. Following the completion of the sale, the director directly owned 3,995 shares in the company, valued at approximately $560,977.90. The trade was a 24.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 1.50% of the company’s stock.

ICU Medical Price Performance

Shares of NASDAQ:ICUI opened at $148.43 on Friday. The firm has a market capitalization of $3.66 billion, a price-to-earnings ratio of -97.65 and a beta of 0.83. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.44 and a quick ratio of 1.17. The business’s 50 day simple moving average is $127.51 and its 200-day simple moving average is $128.69. ICU Medical, Inc. has a 12 month low of $107.00 and a 12 month high of $175.51.

ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $2.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.43 by $0.60. The firm had revenue of $533.30 million during the quarter, compared to analysts’ expectations of $511.46 million. ICU Medical had a positive return on equity of 7.24% and a negative net margin of 1.56%.ICU Medical’s revenue was down 8.9% on a year-over-year basis. During the same period in the previous year, the firm posted $1.59 earnings per share. ICU Medical has set its FY 2025 guidance at 7.350-7.650 EPS. As a group, equities analysts forecast that ICU Medical, Inc. will post 4.11 earnings per share for the current fiscal year.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.